Akebia CFO sells 34,951 shares at $1.39

Akebia Therapeutics, Inc. executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer, reported a sale of common stock.

Rhea-AI Filing Summary

Akebia Therapeutics, Inc. executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer, reported a sale of common stock. On February 2, 2026, he sold 34,951 shares at $1.39 per share.

According to the filing, the sale was made automatically by Akebia to cover tax withholding obligations tied to the vesting and settlement of one-third of his restricted stock units granted on January 31, 2025. The transaction was carried out under a Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owns 672,635 shares of Akebia common stock directly.

Insider Trade Summary

Net Seller: 34,951 shares

Net Sell 1 txn

Insider Ostrowski Erik

Role SVP, CFO, CBO & Treasurer

Sold 34,951 shs ($49K)

Type	Security	Shares	Price	Value
Sale	Common Stock	34,951	$1.39	$49K

Holdings After Transaction: Common Stock — 672,635 shares (Direct)

Footnotes (2)

1. F1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.
2. F2. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Akebia Therapeutics (AKBA) report for its CFO?

Akebia reported that SVP, CFO, CBO and Treasurer Erik Ostrowski sold 34,951 shares of common stock. The sale occurred on February 2, 2026 at $1.39 per share and was disclosed in a Form 4 insider trading report.

Why did Akebia Therapeutics (AKBA) CFO sell 34,951 shares of stock?

The 34,951-share sale was made automatically by Akebia to cover tax withholding obligations. It was connected to the vesting and settlement of one-third of Ostrowski’s restricted stock units that were granted on January 31, 2025.

Was the Akebia (AKBA) CFO’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan. This plan was adopted by Erik Ostrowski on September 8, 2025, providing a pre-arranged framework for selling shares over time.

How many Akebia (AKBA) shares does the CFO own after this Form 4 transaction?

After selling 34,951 shares, Erik Ostrowski beneficially owns 672,635 shares of Akebia common stock. The filing classifies this as direct ownership, meaning the shares are held in his own name rather than through an intermediary entity.

What type of security was involved in the Akebia (AKBA) insider transaction?

The transaction involved Akebia Therapeutics common stock. One line item shows the sale of 34,951 common shares at $1.39 each, reported as a non-derivative security in Table I of the Form 4 insider filing.

What triggered the tax withholding sale reported by Akebia (AKBA)?

The sale was triggered by the vesting and settlement of one-third of restricted stock units granted to Ostrowski on January 31, 2025. Akebia automatically sold 34,951 shares to satisfy associated tax withholding obligations for this vesting event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ostrowski Erik

(Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST ST.

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CFO, CBO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S		34,951(1)(2)	D	$1.39	672,635	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

2. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

Remarks:

	/s/ Carolyn M. Rucci, attorney-in-fact for Erik Ostrowski	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.